Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 24, Art. 31 (pp. 414-430)    |    2023       

»

Experimental study of the effectiveness of the use of disodium glycyl-cysteinyl-glutamate inosine and ademethionine preparations on a model of ethanol-induced toxic liver damage

Orlov Yu.V., Kuzmich V.G., Gaiduk S.V., Sinyachkin D.A., Antushevich A. E.

Kirov Military Medical Academy of the Ministry of Defense of the Russian Federation

Brief summary

The increase in the incidence of cirrhosis of the liver makes the urgent problem of finding new drugs for the treatment of toxic liver damage of various etiologies and the prevention of the development of their complications, such as fibrosis and cirrhosis of the liver. Currently, much attention is paid to preparations of glutathione disulfide in the complex therapy of toxic liver lesions. At the same time, information about the hepatoprotective and antifibrotic effects of glutathione disulfide preparations in the modern scientific literature is limited, which was the reason for this study. In the course of an experimental study on laboratory animals, a comparative evaluation of the effectiveness of the use of inosine glycyl-cysteinyl-glutamate disodium and ademethionine in the treatment of experimental toxic hepatitis and liver cirrhosis induced by the administration of ethanol in combination with N - nitrosodimethylamine was carried out. Laboratory animals, after modeling ethanol/nitrosodimethylamine induced liver cirrhosis, were divided into four groups. The first group - animals with ethanol/nitrosodimethylamine induced hepatitis and cirrhosis of the liver without treatment. The second group - animals with ethanol/nitrosodimethylamine induced hepatitis and cirrhosis of the liver were treated with saline solution. The third and fourth groups received preparations of inosine glycyl-cysteinyl-glutamate disodium and ademethionine, respectively. Intact animals that did not receive toxicants and medications were allocated to a separate group. The studied drugs were administered intraperitoneally for 6 weeks. In the course of the study, the biochemical parameters of cytolytic and cholestatic liver damage syndromes were evaluated, the histological picture of toxic liver damage and the effectiveness of the studied drugs were evaluated. Based on the data obtained, it can be argued that the presence of hepatoprotective and antifibrotic effects in the studied drugs is more pronounced in inosine glycyl-cysteinyl-glutamate disodium, which indicates the expediency of its use in the treatment of toxic liver damage of various etiologies and prevention of the development of their complications.


Key words

toxic liver damage; toxic hepatitis; liver fibrosis; liver cirrhosis; N-nitrosodimethylamine; ethanol; inosine glycyl-cysteinyl-glutamate disodium; ademethionine

Reference list

1. Ivashkin V.T., Maevskaya M.V., Pavlov Ch.S., i dr. Klinicheskie rekomendacii Rossiiskogo obshestva po izycheniu pecheni po vedeniu vzroslih pacientov s alkogolnoi boleznu pecheni. Rossiiskii jyrnal gastroenterologii, gepatologii, koloproktologii. 2017; 27(6): 20-40. DOI: 10.22416/1382-4376-2017-27-6-20-40.


2. Lazebnik L.B., Golovanova E. V., Eremina E. U., i dr. Klinicheskie rekomendacii: alkogolnaya bolezn pecheni y vzroslih. Terapiya. 2020; 6.4(38): 10-35. - DOI 10.18565/therapy.2020.4.10-35.


3. Dasarathy S. Nutrition and alcoholic liver disease: effects of alcoholism on nutrition, effects of nutrition on alcoholic liver disease, and nutritional therapies for alcoholic liver disease. Clin. LiverDis. 2016; 20(3): 535-550. doi: 10.1016/j.cld.2016.02.010.


4. Max G.G., Fullman N., Hawley C. et al. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018; 392: 1015-1035. http: dx.doi.org/10.1016/S0140-6736(18)31310-2.


5. Roth G.A., Abate D., Abate K.H. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 1736-1788.


6. Antyshevich A.E., Basharin V.A., Reinuk V.L., Bygaev P.A. Effektivnost inozina glicil-cisteinil-glytamata dinatriya i piridoksina gidrohlorida pri ostrom otravlenii nesimmetrichnim dimetilgidrazinom // Vestnik Rossiiskoi voenno-medicinskoi akademii. 2018; 1 (61): 164-167.


7. EASL Clinical PracticalGuidelines: Management of Alcoholic Liver Disease. J. Hepatol. 2018; 69:154-181.


8. Sonika U., Jadaun S., Ranjan G., et al. Alcohol-related acute-on-chronic liver failure-Comparison of various prognostic scores in predicting outcome. Indian J. Gastroenterol. 2018; 37(1): 50-57. doi: 10.1007/s12664-018-0827-z.


9. Cirkynov V.M., Prokopchik N.I., Andreev V.P. Aytoimmynnie holestaticheskie porajeniya jelchnih protokov. Gepatologiya i gastroenterologiya. 2021; 5(2): 99-100. https://doi. org/10.25298/2616-5546-2021-5-2-99-100.


10. Dorovskih V.A., Simonova N.V., Pereverzev D.I., i dr. Eksperimentalnaya i klinicheskaya farmakologiya. 2017; 80 (4): 18 -22.


11. Izveshenie o nejelatelnoi reakcii ili otsytstvii terapevticheskogo effekta lekarstvennogo preparata. -URL: http://www.roszdravnadzor.ru/drugs/monitpringlp/documents/547. - (data obrasheniya 18.04.2019).


12. Evseenko D.A., Dyndarov Z.A. Eksperimentalnoe formirovanie cirroza pecheni jivotnih v laboratornih ysloviyah. Hepatology and Gastroenterology. 2018; 2: 122-128.


13. Blinov D.E., Kyhareva E.I., Politidis R.R. Osnovnie patogeneticheskie mehanizmi fibroza pecheni i ih osobennosti pri virysnom gepatite B. Trydnii pacient. 2021; 19 (6): 50-53. doi: 10.224412/2074-1005-2021-6-50-53.


14. Cimmerman Ya.S. Fibroz pecheni: patogenez, metodi diagnostiki, perspektivi lecheniya. Klinicheskaya farmakologiya i terapiya. 2017; 26 (1): 54-58.


15. Kylebina E.A., Syrkov A.N. Mehanizmi formirovaniya fibroza pecheni: sovremennie predstavleniya. Pediatriya. Jyrnal im. G.N. Speranskogo. 2019; 98 (6): 166-170.


16. Krukov E.V., Kazakov S.P., Semiserin V.A., i dr. Ispolzovanie pryamih markerov fibroza pecheni v diagnostike nealkogolnoi jirovoi bolezni pecheni y voennoslyjashih kontraktnoi slyjbi. Medicinskii alfavit No 19. 2016; 3: 85-86.


17. Patlysov E.P., Kolesnik V.V., Chernov V.S., i dr. Pynkcionnaya biopsiya pecheni - proshloe ili nastoyashee? Yralskii medicinskii jyrnal. 2019: 3 (171): 77-82.


18. Orlov U.V., Bygaev P.A., Halimov U.Sh. i dr. Effektivnost disylfidov glytationa v lechenii toksicheskih gepatitov i fibrozov pecheni. Voenno-medicinskii jyrnal. 2018; 339 (11): 21-27.


19. Geptral. Spravochnik lekarstv RLS: instrykciya, primenenie i opisanie preparata sAMe. - Rejim dostypa: https://www.rlsnet.ru/tn_index_id_10764.htm (data obrasheniya 29.01.2018).


20. Moliksan. Spravochnik lekarstv RLS: instrykciya, primenenie i opisanie preparata IG. - Rejim dostypa: https://www.rlsnet.ru/tn_index_id_23291.htm (data obrasheniya 29.01.2018).


21. Tew K.D. Redox in redux: emergent roles for glutathione S-transferase P(GSTP) in regulation of cell signaling and S-glutathionylatio. Biochem. Pharmacol. 2007; 73 (9): 1257-1269.